67308-25-2 Usage
General Description
(S)-N-Boc-6-fluorotryptophan is a chemical compound that is comprised of a tryptophan molecule with a fluorine atom attached to the 6th position, and a Boc protecting group attached to the nitrogen atom. The compound is a derivative of the amino acid tryptophan, and the Boc protecting group is commonly used in peptide synthesis to protect the amine group. The addition of the fluorine atom to tryptophan can alter its properties and may be used to study protein-ligand interactions or in the synthesis of new pharmaceutical compounds.(S)-N-Boc-6-fluorotryptophan is a versatile chemical that has potential applications in various fields including pharmaceuticals, biochemistry, and materials science.
Check Digit Verification of cas no
The CAS Registry Mumber 67308-25-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,7,3,0 and 8 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 67308-25:
(7*6)+(6*7)+(5*3)+(4*0)+(3*8)+(2*2)+(1*5)=132
132 % 10 = 2
So 67308-25-2 is a valid CAS Registry Number.
InChI:InChI=1/C16H19FN2O4/c1-16(2,3)23-15(22)19-13(14(20)21)6-9-8-18-12-7-10(17)4-5-11(9)12/h4-5,7-8,13,18H,6H2,1-3H3,(H,19,22)(H,20,21)/t13-/m0/s1
67308-25-2Relevant articles and documents
A class of DL-tryptophan compounds, preparation method and applications thereof
-
Paragraph 0058-0061; 0068-0070, (2020/06/17)
The invention provides a DL-tryptophan compound represented by a general formula I or a pharmaceutically acceptable salt thereof, a preparation method and applications thereof, especially applicationsin preparation of RANKL inhibitors. According to the DL-tryptophan compound or the pharmaceutically acceptable salt thereof, an OPG-RANKL-RANK signal system can be intervened by inhibiting the interaction of RANKL-RANK, and the activity of RANKL in osteoclast precursor cells is regulated and controlled, so that formation of osteoclasts is inhibited, and bone resorption is reduced; and the DL-tryptophan compound or the pharmaceutically acceptable salt thereof is expected to play a role in preventing and treating bone metabolic diseases, and brings good news to bone metabolic disease patients.
N-tert-butoxycarbonyl-l-phenylalanine
Paleveda, William J.,Holly, Frederick W.,Veber, Daniel F.
, p. 171 - 171 (2017/05/17)
-
